Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) Return on Sales (2018 - 2025)

BioNexus Gene Lab's Return on Sales history spans 8 years, with the latest figure at 2.14% for Q4 2025.

  • Quarterly results put Return on Sales at 2.14% for Q4 2025, down 201.0% from a year ago — trailing twelve months through Dec 2025 was 0.4% (down 24.0% YoY), and the annual figure for FY2025 was 0.4%, down 23.0%.
  • Return on Sales for Q4 2025 was 2.14% at BioNexus Gene Lab, down from 0.28% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.15% in Q4 2023 to a low of 2.14% in Q4 2025.
  • The 5-year median for Return on Sales is 0.04% (2022), against an average of 0.22%.
  • The sharpest move saw Return on Sales surged 51bps in 2024, then plummeted -201bps in 2025.
  • Year by year, Return on Sales stood at 0.04% in 2021, then crashed by -251bps to 0.05% in 2022, then skyrocketed by 387bps to 0.15% in 2023, then plummeted by -187bps to 0.14% in 2024, then plummeted by -1484bps to 2.14% in 2025.
  • According to Business Quant data, Return on Sales over the past three periods came in at 2.14%, 0.28%, and 0.27% for Q4 2025, Q3 2025, and Q2 2025 respectively.